Leerink Partnrs Predicts Lower Earnings for Elevance Health

Elevance Health, Inc. (NYSE:ELV - Free Report) - Equities researchers at Leerink Partnrs reduced their Q2 2025 EPS estimates for Elevance Health in a research note issued on Tuesday, April 22nd. Leerink Partnrs analyst W. Mayo now anticipates that the company will earn $9.98 per share for the quarter, down from their previous forecast of $10.17. The consensus estimate for Elevance Health's current full-year earnings is $33.96 per share. Leerink Partnrs also issued estimates for Elevance Health's Q1 2026 earnings at $12.79 EPS and Q2 2026 earnings at $11.52 EPS.

ELV has been the subject of several other research reports. Guggenheim reiterated a "buy" rating and issued a $518.00 target price on shares of Elevance Health in a report on Wednesday, April 23rd. Royal Bank of Canada restated an "outperform" rating and set a $478.00 price objective on shares of Elevance Health in a report on Wednesday, April 23rd. Truist Financial raised their price objective on shares of Elevance Health from $480.00 to $510.00 and gave the stock a "buy" rating in a report on Friday, April 11th. Mizuho raised their price objective on shares of Elevance Health from $455.00 to $505.00 and gave the stock an "outperform" rating in a report on Wednesday, April 9th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $485.00 price objective on shares of Elevance Health in a report on Wednesday, April 23rd. Four research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, Elevance Health currently has an average rating of "Moderate Buy" and a consensus price target of $510.38.

Elevance Health Stock Up 0.8 %

Shares of ELV stock traded up $3.43 on Friday, hitting $417.08. The stock had a trading volume of 395,253 shares, compared to its average volume of 1,458,220. The business has a 50 day moving average of $420.88 and a 200 day moving average of $406.73. The stock has a market cap of $94.23 billion, a price-to-earnings ratio of 16.29, a price-to-earnings-growth ratio of 1.18 and a beta of 0.77. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.45 and a quick ratio of 1.50. Elevance Health has a 12-month low of $362.21 and a 12-month high of $567.26.

Elevance Health (NYSE:ELV - Get Free Report) last announced its earnings results on Tuesday, April 22nd. The company reported $11.97 EPS for the quarter, beating the consensus estimate of $10.60 by $1.37. The company had revenue of $48.77 billion during the quarter, compared to the consensus estimate of $46.26 billion. Elevance Health had a net margin of 3.38% and a return on equity of 18.28%.

Elevance Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 25th. Stockholders of record on Tuesday, June 10th will be issued a $1.71 dividend. The ex-dividend date is Tuesday, June 10th. This represents a $6.84 annualized dividend and a dividend yield of 1.64%. Elevance Health's payout ratio is currently 26.69%.

Insider Transactions at Elevance Health

In related news, CFO Mark Kaye sold 4,588 shares of the stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $424.82, for a total value of $1,949,074.16. Following the transaction, the chief financial officer now owns 18,977 shares of the company's stock, valued at $8,061,809.14. This represents a 19.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Ronald W. Penczek sold 443 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $415.13, for a total value of $183,902.59. Following the completion of the transaction, the chief accounting officer now directly owns 1,847 shares in the company, valued at approximately $766,745.11. This represents a 19.34 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 8,535 shares of company stock valued at $3,521,612. 0.29% of the stock is currently owned by company insiders.

Institutional Trading of Elevance Health

Institutional investors have recently added to or reduced their stakes in the business. Accredited Wealth Management LLC purchased a new stake in Elevance Health during the fourth quarter valued at about $25,000. Flagship Wealth Advisors LLC purchased a new stake in shares of Elevance Health during the fourth quarter worth about $26,000. OFI Invest Asset Management purchased a new stake in shares of Elevance Health during the fourth quarter worth about $29,000. WealthTrak Capital Management LLC purchased a new stake in shares of Elevance Health during the fourth quarter worth about $29,000. Finally, Lee Danner & Bass Inc. purchased a new stake in shares of Elevance Health during the fourth quarter worth about $30,000. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.